home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Phacilitate Oncology Leaders' Forum 2007

 
  July 11, 2007  
     
 
Phacilitate Ltd, The Marriott Long Wharf Hotel, Boston, MA
14-16 November 2007


Visit www.phacilitate.co.uk/oncology for the latest program information.
 
 
Organized by: Phacilitate Ltd
Invited Speakers: Visit www.phacilitate.co.uk/oncology for the full list of confirmed speakers, which includes: - Mara G. Aspinall, President, Genetics, Genzyme Corporation - Dr Brent M. Vose, Vice President & Head of Oncology & Infection, AstraZeneca - Dr Peter T. C. Ho, Senior Vice President of Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline - Barry M. Straube, MD, CMS Chief Medical Officer & Director, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services - Kapil Dhingra, MD, Head of the Oncology Global Drug Development Group, Hoffmann-La Roche, Inc - Dr Lawrence Shulman, Chief Medical Officer, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute & Director, Network Development, Dana-Farber/Brigham & Women's Cancer Care - Christopher Seaton, Senior Vice President, Global Business Development & Licensing, Bayer Corporation - Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence - Lee F. Allen, MD, PhD, Cambridge Site Head, Vice President, Medical Research - Oncology Therapeutic Area, Wyeth Research - Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association - Steven D. Harr, Managing Director & Analyst, Morgan Stanley - Dr Roy Baynes, Vice President, Clinical Development, Therapeutic Area Head, Oncology Supportive Care, Amgen, Inc - Dr Stephen Kelsey, Vice President & Head of Exploratory Clinical Development, BioOncology, Genentech, Inc - Dr Doris Slate, Vice President, Scientific Licensing, Johnson & Johnson - Dr Nicholas C. Dracopoli, Vice President, Clinical Discovery Technologies, Bristol-Myers Squibb Pharmaceutical Research Institute - Geert Kolvenbag, MD, PhD, Executive Director of Development, Emerging Oncology Brands, AstraZeneca - Dr David Chang, Vice President, Global Clinical Development, Oncology Therapeutics, Amgen - Jeffrey D. Bloss, MD, Vice President, Clinical Development, Onyx Pharmaceuticals, Inc - Anne E. Hagey, MD, Global Project Head, Oncology Cytotoxics, Abbott Laboratories - Thomas W. Griffin, MD, Executive Director, Therapeutic Area Head, Oncology Therapeutics, North American Medical Affairs, Amgen, Inc - Howard J. Fingert, MD, FACP, Senior Director & Clinical Lead, Signal Transduction Development Program, Pfizer Oncology - Dr Jay Feingold, Assistant Vice President & Multi-Therapeutic Area Head, Global Medical Affairs, Wyeth Research - Dr Neil W. Gibson, Chief Scientific Officer, OSI Pharmaceuticals, Inc - Dr Robert L. Ilaria Jr, Medical Advisor for Oncology, Eli Lilly and Company - Professor James Carmichael, CMO, KuDOS Pharmaceuticals.
 
Deadline for Abstracts: n/a
 
Registration: Visit www.phacilitate.co.uk/oncology for information and online registration.
E-mail: nicola@phacilitate.co.uk
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.